Celon Pharma - EU Taxonomy Data: Eligible & Aligned Revenues, CAPEX & OPEX

Celon Pharma's EU Taxonomy Data Preview

In 2024, Celon Pharma was subject to the Corporate Sustainability Reporting Directive (CSRD)'s requirements, which mandated the company to publish EU Taxonomy disclosures.

The company reported the eligibility and alignment of Turnover, Capital Expenditure (CAPEX) and Operating Expenditure (OPEX) with the EU Taxonomy, helping assess the extent to which its business activities align with Europe's environmental sustainability goals.

Celon Pharma has also provided an activity-level breakdown of its EU Taxonomy disclosures. This granular reporting enhances transparency around which economic activities of Celon Pharma are considered environmentally sustainable and contribute to at least one of the six environmental objectives defined under the EU Taxonomy framework.

turnoveropexcapex

Metric (tonnes)	2025	2024	2023	2022 - 2017
Total Taxonomy Aligned A1 Turnover Portion of total company turnover generated from economic activities that are eligible under the EU Taxonomy and meet all alignment requirements, including substantial contribution, Do No Significant Harm (DNSH), and minimum safeguards.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data.	Data available for purchase 0000000
Total Taxonomy Eligible A Turnover Total turnover of the company associated with activities considered eligible under the EU Taxonomy, regardless of whether they meet alignment criteria.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data. ^a	Copy restricted. Please purchase to unlock this data. ^b	Data available for purchase 0000000
Total Taxonomy Non-Eligible B Turnover Total turnover of the company associated with activities that are not listed as eligible under the EU Taxonomy.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data. ^a	Copy restricted. Please purchase to unlock this data. ^b	Data available for purchase 0000000

Metric (tonnes)	2025	2024	2023	2022 - 2017
Total Taxonomy Aligned A1 Opex Portion of total company OPEX generated from economic activities that are eligible under the EU Taxonomy and meet all alignment requirements, including substantial contribution, Do No Significant Harm (DNSH), and minimum safeguards.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data.	Data available for purchase 0000000
Total Taxonomy Eligible A Opex Total OPEX of the company associated with activities considered eligible under the EU Taxonomy, regardless of whether they meet alignment criteria.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data. ^a	Copy restricted. Please purchase to unlock this data. ^b	Data available for purchase 0000000
Total Taxonomy Non-Eligible B Opex Total OPEX of the company associated with activities that are not listed as eligible under the EU Taxonomy.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data. ^a	Copy restricted. Please purchase to unlock this data. ^b	Data available for purchase 0000000

Metric (tonnes)	2025	2024	2023	2022 - 2017
Total Taxonomy Aligned A1 Capex Portion of total company CAPEX generated from economic activities that are eligible under the EU Taxonomy and meet all alignment requirements, including substantial contribution, Do No Significant Harm (DNSH), and minimum safeguards.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data.	Data available for purchase 0000000
Total Taxonomy Eligible A Capex Total CAPEX of the company associated with activities considered eligible under the EU Taxonomy, regardless of whether they meet alignment criteria.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data. ^a	Copy restricted. Please purchase to unlock this data. ^b	Data available for purchase 0000000
Total Taxonomy Non-Eligible B Capex Total CAPEX of the company associated with activities that are not listed as eligible under the EU Taxonomy.	Copy restricted. Please purchase to unlock this data.	Copy restricted. Please purchase to unlock this data. ^a	Copy restricted. Please purchase to unlock this data. ^b	Data available for purchase 0000000

Verified Sources Behind Celon Pharma’s EU Taxonomy Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Celon Pharma’s data sources below and access millions more through our Disclosure Search.

a. Celon Pharma's Management report 2024

b. Celon Pharma's Management report 2023

Insights into Celon Pharma's Revenues from Sustainable Activities

In 2024, Celon Pharma reported EU Taxonomy-eligible revenues of PLN 178.26 million, representing 86% of its total turnover. Of this amount, PLN 0 of Celon Pharma's revenues was classified as EU Taxonomy-aligned, indicating that 0% of the revenue-generating activities undertaken by the company substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).^a

Insights into Celon Pharma's CAPEX from Sustainable Activities

In 2024, Celon Pharma reported EU Taxonomy-eligible CAPEX of PLN 15.93 million,representing 63.8% of its total CAPEX. Of this amount, PLN 0 of Celon Pharma's CAPEX was classified as EU Taxonomy-aligned, indicating that 0% of the company's investments were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).^a

Insights into Celon Pharma's OPEX from Sustainable Activities

In 2024, Celon Pharma reported EU Taxonomy-eligible OPEX of PLN 8.83 million,representing 11.8% of its total operating expenses (OPEX). Of this amount, PLN 0 of Celon Pharma's OPEX was classified as EU Taxonomy-aligned, indicating that 0% of the company's operating expenses were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).^a

Welcome Back to Tracenable

Sign in to your account

Celon Pharma SA

Celon Pharma's EU Taxonomy Data Preview

Verified Sources Behind Celon Pharma’s EU Taxonomy Data

Insights into Celon Pharma's Revenues from Sustainable Activities

Insights into Celon Pharma's CAPEX from Sustainable Activities

Insights into Celon Pharma's OPEX from Sustainable Activities

Explore Peer Companies

Neuca SA

Selvita SA

Voxel SA

Centrum Medyczne Enel Med SA

Mercator Medical SA

EMC Instytut Medyczny SA